Abstract

Simple SummaryFor patients with early-stage hepatocellular carcinoma, it is important to know whether liver transplantation offers a survival benefit over liver resection. Patients receiving transplantation often have different characteristics in terms of their cancer stage and liver function compared to those being resected. This makes a comparison of the two treatment modalities challenging. This article presents a comprehensive review of research articles comparing these two treatments and discusses their strengths and weaknesses. Furthermore, we suggest a new research design that uses a treatment guideline to help ensure that the groups are more comparable. Hereby, we enable future studies to assess whether liver transplantation offers a survival benefit over liver resection in patients that are eligible for both treatments.For patients presenting with hepatocellular carcinoma within the Milan criteria, either liver resection or liver transplantation can be performed. However, to what extent either of these treatment options is superior in terms of long-term survival is unknown. Obviously, the comparison of these treatments is complicated by several selection processes. In this article, we comprehensively review the current literature with a focus on factors accounting for selection bias. Thus far, studies that did not perform an intention-to-treat analysis conclude that liver transplantation is superior to liver resection for early-stage hepatocellular carcinoma. In contrast, studies performing an intention-to-treat analysis state that survival is comparable between both modalities. Furthermore, all studies demonstrate that disease-free survival is longer after liver transplantation compared to liver resection. With respect to the latter, implications of recurrences for survival are rarely discussed. Heterogeneous treatment effects and logical inconsistencies indicate that studies with a higher level of evidence are needed to determine if liver transplantation offers a survival benefit over liver resection. However, randomised controlled trials, as the golden standard, are believed to be infeasible. Therefore, we suggest an alternative research design from the causal inference literature. The rationale for a regression discontinuity design that exploits the natural experiment created by the widely adopted Milan criteria will be discussed. In this type of study, the analysis is focused on liver transplantation patients just within the Milan criteria and liver resection patients just outside, hereby ensuring equal distribution of confounders.

Highlights

  • Over the years, a multitude of treatment options and strategies for hepatocellular carcinoma (HCC) were developed

  • The survival advantage of liver transplantation (LT) vs. liver resection (LR) is fundamental in almost all LT discussions

  • In the currently available literature, most studies in which no ITT analysis is performed conclude that LT is superior to LR, whereas studies using an ITT analysis conclude that survival is comparable

Read more

Summary

Introduction

A multitude of treatment options and strategies for hepatocellular carcinoma (HCC) were developed. For the subset of patients with early HCC (i.e., within the Milan Criteria (MC)) that have a good liver function and no portal hypertension, both treatments can be performed [1,2]. This subset is sizable and consists of 20–25% of the surgical HCC population [3,4,5]. Comparisons of the two treatments are frequently attempted as the difference in 5-year overall survival (OS; i.e., the treatment effect) is the fundament of many discussions These range from the preferred first-line treatment and prioritisation, the role of salvage transplantation, to the ethicality of living donor liver transplantation (LDLT) [6]. This review focuses on the current evidence comparing LT to LR with special attention to lacunas and logical conflicts besides the application of causal inference techniques as the best alternative to a randomised controlled trial (RCT)

Objectives
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call